Discover 774 paid clinical trials in District of Columbia. Search by city or condition to find a research study near you that matches your needs across various therapeutic areas.
Filter
1
Filter results
Results: 774
Active & Responsive
A Study of Mezagitamab in Adults With Chronic Primary Immune Thrombocytopenia
for
Immune Thrombocytopenic Purpura (ITP)
Location: Boston MA, Philadelphia PA, Norfolk VA, Greenville NC,
Sponsor: Takeda
Sex: All
Age: 18+
Code: NCT06722235
Phase 3, Recruiting
Active & Responsive
Topical Ketotifen 0.25% for Secondary Vestibulodynia
Location: Boston MA, New Haven CT, New York NY, Philadelphia PA,
Sponsor: Mezzion Pharma Co. Ltd
Sex: All
Age: 12 - 18
Code: NCT05918211
Phase 3, Recruiting
Active & Responsive
VMD-928 Monotherapy and in Combination With Pembrolizumab to Treat TrkA Overexpression Driven Solid Tumors or Lymphoma
for
Head and Neck Carcinoma, Adenoid Cystic Carcinoma, Lung Cancer,
Location: Hartford CT, New York NY, Englewood NJ, Florham Park NJ,
Sponsor: VM Oncology, LLC
Sex: All
Age: 18 - 70+
Code: NCT03556228
Phase 1, Phase 2, Recruiting
Active & Responsive
Testing a Standardized Approach to Surgery and Chemotherapy for Type I Pleuropulmonary Blastoma or the Addition of an Anti-cancer Drug, Topotecan, to the Usual Treatment for Types II and III Pleuropulmonary Blastoma
for
Pleuropulmonary Blastoma
Location: Halifax, Boston MA, Quebec, Sherbrooke,
Sponsor: Children's Oncology Group
Sex: All
Age: 0 - 21
Code: NCT06647953
Phase 3, Recruiting
Active & Responsive
RAGE Inhibition to Decrease Cardiotoxicity in Women With Early Breast Cancer
for
Cancer Related Cognitive Decline, Non-metastatic Breast Cancer
Location: Hackensack NJ, Washington D.C. DC
Sponsor: Georgetown University
Sex: Female
Age: 18+
Code: NCT05256745
Phase 1, Phase 2, Recruiting
Active & Responsive
Prevalence of Antibodies and Cytokines in Participants With Chronic Granulomatous Disease
for
Chronic Granulomatous Disease (CGD)
Location: Augusta ME, Boston MA, Providence RI, Concord NH,
Sponsor: Ensoma
Sex: All
Age: 0+
Code: NCT06605378
Recruiting
Active & Responsive
A Clinical Study of MK-2870 Alone or With Other Treatments to Treat Gastrointestinal Cancers (MK-9999-02A)
Location: Mineola NY, New York NY, Montreal, Ottawa,
Sponsor: Merck Sharp & Dohme LLC
Sex: All
Age: 18+
Code: NCT06428409
Phase 1, Phase 2, Recruiting
Active & Responsive
A Prospective Analysis of Long-Term Clinical Outcomes and 3D Spine Growth in Anterior Vertebral Body Tethering
for
Scoliosis Idiopathic
Location: New York NY, Philadelphia PA, Washington D.C. DC,
Sponsor: Pediatric Spine Foundation
Sex: All
Age: 0 - 18
Code: NCT04914507
Recruiting
Active & Responsive
Mood Alterations in the Patients With Non-Muscle Invasive Bladder Cancer Treated With BCG
for
Non-Muscle Invasive Bladder Cancer
Location: Washington D.C. DC
Sponsor: Johns Hopkins University
Sex: All
Age: 18+
Code: NCT05672615
Recruiting
Active & Responsive
A Clinical Study of Ifinatamab Deruxtecan (I-DXd) in People With Metastatic Prostate Cancer (MK-2400-001)
for
Prostate Cancer, Prostatic Neoplasms
Location: Boston MA, New Haven CT, West Haven CT, New York NY,
Sponsor: Merck Sharp & Dohme LLC
Sex: Male
Age: 18+
Code: NCT06925737
Phase 3, Recruiting
Active & Responsive
Pembrolizumab With or Without Maintenance Sacituzumab Tirumotecan (Sac-TMT; MK-2870) in Metastatic Squamous Non-small Cell Lung Cancer (NSCLC) [MK-2870-023]